Skip to Content

Vanadom (carisoprodol) Disease Interactions

There are 3 disease interactions with Vanadom (carisoprodol):

Major

Carisoprodol (Includes Vanadom) ↔ Porphyria

Severe Potential Hazard, High plausibility

Applies to: Porphyria

The use of carisoprodol is contraindicated in patients with acute intermittent porphyria. Carisoprodol is partially metabolized to the pharmacologically active meprobamate, which has been reported to precipitate acute attacks of porphyria in susceptible patients.

References

  1. Hazen PG "Pseudoporphyria in a patient receiving carisoprodol/aspirin therapy." J Am Acad Dermatol 31 (1994): 500
  2. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
  3. "Product Information. Soma (carisoprodol)." Meda Pharmaceuticals, Somerset, NJ.
Moderate

Carisoprodol (Includes Vanadom) ↔ Drug Dependence

Moderate Potential Hazard, Moderate plausibility

Applies to: Alcoholism, Drug Abuse/Dependence

Carisoprodol is partially metabolized to meprobamate, a pharmacologically active agent with known addictive potential. According to the manufacturer, abrupt cessation of carisoprodol 100 mg/kg/day (approximately 5 times the recommended daily adult dosage) was associated with mild withdrawal symptoms such as abdominal cramps, insomnia, headache, nausea and chills in some study subjects. In clinical use, psychological dependence and abuse have been rare. Nevertheless, therapy with carisoprodol should be administered cautiously in addiction-prone individuals, such as those with a history of alcohol or substance abuse. It may be prudent to refrain from dispensing large quantities of medication to these patients.

References

  1. Morse RM, Chua L "Carisoprodol dependence: a case report." Am J Drug Alcohol Abuse 5 (1978): 527-30
  2. "Product Information. Soma (carisoprodol)." Meda Pharmaceuticals, Somerset, NJ.
  3. Elder NC "Abuse of skeletal muscle relaxants." Am Fam Physician 44 (1991): 1223-6
View all 4 references
Moderate

Carisoprodol (Includes Vanadom) ↔ Renal/Liver Disease

Moderate Potential Hazard, High plausibility

Applies to: Liver Disease, Renal Dysfunction

Carisoprodol is primarily converted in the liver to several metabolites, one of which (meprobamate) is pharmacologically active. The metabolites and a small amount of the parent drug are excreted in the urine. Patients with impaired renal and/or hepatic function may be at greater risk for adverse effects due to drug and metabolite accumulation. Therapy with carisoprodol should be administered cautiously in such patients.

References

  1. "Product Information. Soma (carisoprodol)." Meda Pharmaceuticals, Somerset, NJ.

Vanadom (carisoprodol) drug Interactions

There are 698 drug interactions with Vanadom (carisoprodol)

Vanadom (carisoprodol) alcohol/food Interactions

There is 1 alcohol/food interaction with Vanadom (carisoprodol)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide